| Titre : | Psychotropics and COVID-19 : An analysis of safety and prophylaxis (2021) |
| Auteurs : | JAVELOT HERVÉ ; STRACZEK CÉLINE ; MEYER GUILLAUME ; GITAHY FALCAO FARIA CLARA ; WEINER LUISA ; DRAPIER DOMINIQUE ; FAKRA ERIC ; FOSSATI PHILIPPE ; WEIBEL SÉBASTIEN ; DIZET SOPHIE ; LANGREE BASTIEN ; MASSON MARC ; GAILLARD RAPHAËL ; LEBOYER MARION ; LLORCA PIERRE-MICHEL ; HINGRAY CORALINE ; HAFFEN EMMANUEL ; YRONDI ANTOINE |
| Type de document : | Article |
| Dans : | ENCEPHALE (6 vol 47, 2021) |
| Article en page(s) : | 564-588 |
| Langues: | Français |
| Descripteurs |
[SANTEPSY] BENEFICE RISQUE [SANTEPSY] BENEFICE THERAPEUTIQUE [SANTEPSY] CORONAVIRUS [SANTEPSY] PANDEMIE [SANTEPSY] PATHOLOGIE PSYCHIATRIQUE [SANTEPSY] PSYCHOTROPE [SANTEPSY] REVUE DE LA LITTERATURE |
| Mots-clés libres: | COVID-19 |
| Résumé : | "The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients ? Secondly, are there any positive side effects of these substances against SARS-CoV-2 ? Our aim was to analyze usage safety of psychotropics during COVID-19; therefore, herein, we have studied : (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications; (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information available today for these risks, categorized by mental health disorder, for the following: schizophrenia, bipolar disorder, anxiety disorder, ADHD, sleep disorders and suicidal risk. The matter of psychoactive substance use during the pandemic is also analyzed in this paper, and guideline websites and publications for psychotropic treatments in the context of COVID-19 are referenced during the text, so that changes on those guidelines and eventual interaction between psychotropics and COVID-19 treatment medication can be reported and studied. Finally, we also provide a literature review of the latest known antiviral properties of psychotropics against SARS-CoV-2 as complementary information. [résumé d'auteur]" |
| En ligne : | https://www.em-premium.com/article/1489257 |
Bibliothèque Médicale et Professionnelle
Bibliothèque Médicale & Professionnelle
Accueil
Sélection de la langue
Se connecter
Adresse
Bibliothèque Médicale et Professionnelle04 74 52 28 07
contact
